Citations

Clear

2960 citation(s) found for "Kim, P".

Living liver donor safety: Early postoperative considerations of living liver donation guidelines from the ILTS-iLDLTG consensus conference
Sayed, Blayne Amir, Tejedor, Marta , Kathirvel, Manikandan , Bhangui, Prashant , Ghanekar, Anand, Kasahara, Mureo , Scatton, Olivier, Ghobrial, Mark, Klair, Tarunjeet , Rajakumar, Akila , Bezinover, Dimitri , Bittermann, Therese , Don, C, Luzzi, Carla , Tsien, Cynthia , Egawa, Hiroto , Ascher, Nancy L. , Bröering, Dieter C. , Chen, Chao‐Long , Lerut, Jan , Mas, Valeria R. , Taner, Timuçin , Vyas, Mary, Wiggins, Chantal, Olthoff, Kim M. , Rela, M, Selzner, Nazia, Sayed, Blayne A. , Bhangui, Prashant , Rammohan, Ashwin , Selzner, Nazia , Tejedor, Marta , Sayed, Blayne A , Chadha, Ryan , Ivanics, Tommy , Kim, Dong‐Sik , Scatton, Olivier , Ghobrial, Mark, Sudhindran, S , Benedetto, Fabrizio Di , Burra, Patrizia , Hirschfield, Gideon M. , Terrault, Norah A. , Wiggins, Chantal, Fung, John J. , Heimbach, Julie K. , Selzner, Nazia

Mayo Clinic

Liver Transplantation | December 18, 2025 | Volume: 32 | Issue: 6 | Pages: 913-924

10.1097/lvt.0000000000000791 | PMID 41410428 Get It

Living donor liver transplantation (LDLT) is a life-saving procedure for patients with end-stage liver disease. As its use expands worldwide, ensuring the safety and well-being of live liver donors (LLD) is of paramount importance. Published evidence on early postoperative complications after living donor hepatectomy—those occurring within 90 days of surgery—is limited, and standardized postoperative care protocols are lacking. The International Liver Transplantation Society (ILTS) and the International Living Donor Liver Transplantation Group (iLDLT Group) convened a consensus conference in Toronto in March 2025 to develop guidelines for the safe care of the LLDs. This manuscript details the recommendations on early postoperative considerations for the safety of LLDs developed by Working Group III (WGIII) of the Consensus Scientific Committee, using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system for assessment of recommendations, and the Danish model of consensus. WGIII addressed four key areas: (1) standardized postoperative care, (2) early biliary complications, (3) early postoperative liver dysfunction, and (4) early postdischarge follow-up. This report emphasizes the need for vigilant postoperative monitoring in specialized units, with access to experienced providers and defined clinical pathways. Structured clinical and psychosocial follow-up protocols, perioperative prophylaxis for surgical site infections and venous thromboembolism, and management of early biliary and vascular complications are discussed. These may help standardize care, reduce complications and improve short-term outcomes in LLDs.
Long-term considerations following living liver donation—Guidelines from the 2025 ILTS-iLDLT consensus conference on living liver donor safety
Sayed, Blayne A. , Jung, Dong-Hwan, Watt, Kymberly D. , Maluf, Daniel G. , Zhu, Zhi‐Jun , Eghtesad, Bijan , Minnee, Robert C. , James, Paul M., Man, Nancy Kwan, Liapakis, AnnMarie , Fipps, David C. , Taner, Timuçin , Wiggins, Chantal, Ascher, Nancy L. , Mas, Valeria, Chen, Chao‐Long, Vyas, Mary, Suk-Suh, Kyung, Broering, Dieter , Lerut, Jan , Olthoff, Kim M. , Rela, Mohamed, Fipps, David C , Sayed, Blayne A , Chan, Albert C Y , Rammohan, Ashwin , Shankar, Sadhana , Syn, Nicholas L. X. , Mathew, Johns Shaji , Bhangui, Prashant , Jung, Dong‐Hwan , Pomfret, Elizabeth , Roberts, John P. , Selzner, Markus , Chan, Albert , Chaudhary, Abhideep , Eguchi, Susumu , James, Paul, Goldaracena, Nicolás , Kodali, Sudha , Kim, Jong Man , Wiggins, Chantal, Terrault, Norah A. , Burra, Patrizia , Hirschfield, Gideon M. , Heimbach, Julie K. , Selzner, Nazia , Rela, Mohamed

Mayo Clinic

Liver Transplantation | December 18, 2025 | Volume: 32 | Issue: 8 | Pages: 1194-1209

10.1097/lvt.0000000000000790 | PMID 41410423 Get It

Living liver donation is a critical component for addressing organ shortage and improving outcomes for patients with end-stage liver disease. As the prevalence of living donor liver transplantation (LDLT) increases worldwide, understanding and optimizing long-term donor health is paramount. The 2025 International Liver Transplantation Society and International Living Donor Liver Transplantation Society (ILTS-iLDLT) Consensus Conference convened experts in the field of liver transplantation to establish evidence-based guidelines focused on the long-term medical, psychological, and social considerations following living liver donation. The aim of this working group was to integrate current evidence and expert consensus on donor follow-up protocols, risk assessment, and management strategies to promote long-term donor health, quality of life, and living liver donor programs globally to safeguard the welfare of this unique population.
Identifying global trends from case reports of fibrodysplasia ossificans progressiva: a scoping review
Scott, Christiaan, Mukaddam, Mona Al, Davis, Michelle, Cunto, Carmen L. De, Hsiao, Edward C. , Pignolo, Robert J., Schwegler, Odette , Artyomenko, Alexander, Croskery, Kim, Hanman, Kate, Sanchot, Boris, Warnants, Emma , Kaplan, Frederick S., Scott, Christiaan , Hsiao, Edward C , Scott, Christiaan, Mukaddam, Mona Al, Davis, Michelle, Cunto, Carmen L. De, Pignolo, Robert J., Schwegler, Odette , Artyomenko, Alexander, Croskery, Kim, Hanman, Kate, Sanchot, Boris, Warnants, Emma , Kaplan, Frederick S.

Mayo Clinic

Therapeutic Advances in Musculoskeletal Disease | December 18, 2025 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/1759720x251407060 | PMID 41427122 Get It

Background: Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare, disabling, genetic disorder characterized by progressive heterotopic ossification (HO). FOP care pathways are complex, and there are many underrepresented patients globally. Objectives: This scoping review aimed to identify global FOP case reports and investigate real-world management practices. Evidence sources, eligibility criteria, and charting methods: International/local databases and congress proceedings were searched. Publications reporting patient-level data for ⩾1 patient with an FOP primary diagnosis, published January 2000–January 2024, were eligible. Publication details, patient demographics, disease presentation, and care pathway were extracted. Data were charted through categorization of themes and frequency analyses. Results: Of 6064 publications screened, 369 were eligible, reporting on 541 patients with FOP. Most publications (82.4% (304/369)) reported an individual case; the remaining reported 2–25 cases. Cases were from 57 countries, most commonly in the Asia/Pacific region (47.0% (254/541)). Most patients had reportedly seen a single specialist (64.8% (59/91)), and care from multidisciplinary teams was reported for only 5.5% (5/91). HO (84.7% (458/541)) and great toe malformations (66.7% (361/541)) were the most commonly reported signs, though mobility limitations (46.2% (96/208)) and growths/lesions (38.5% (80/208)) were most common before diagnosis. The predominant drug classes reported for FOP treatment were corticosteroids (52.6% (102/194)) and nonsteroidal anti-inflammatory drugs (39.7% (77/194)). Surgeries were reported in 35.1% (190/541) of patients. Where specified, the most common surgery types were malformation correction/bone resection (43.6% (78/179)) and biopsies (34.1% (61/179)). Conclusion: This scoping review synthesized valuable real-world insights from case reports of FOP, potentially supporting outreach initiatives in underserved regions and facilitating shared learnings on diagnosis and treatment. Although the inherent selection bias of case studies toward atypical cases limits definitive conclusions, some global trends in the clinical management practices were revealed.
Palliative Care Staff Attitudes Toward Music Therapy for Hospitalized Adult Patients
Carney, Kim , Wiste, Rachel M., Cutshall, Susanne M. , Wood, Christina M., Gentes, Rachel C., Larsen, Brianna E. , Tiwaa, Nana A. , Tetlie, Amelia E., Mackey, Regina M. , Carney, Katherine A , Wood, Christina

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | December 18, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/10499091251407097 | PMID 41408945 Get It

Purpose There is emerging evidence that music therapy (MT) is an effective tool within palliative care to manage patients’ complex needs. This performance improvement project aimed to assess palliative care staff members’ attitudes toward the current utilization of MT within the institution’s hospital-based interdisciplinary practices. Methods Eighty-four staff members practicing within hospital-based palliative care teams were invited to complete a voluntary anonymous mixed methods survey about their impressions of current MT integration. Survey questions inquired about reasons for MT referral, most common pertinent symptoms, perceived benefit to patients, future suggestions for growth, unexpected experiences, and perceived personal benefit to staff. Major Findings Fifty-one staff members (61%) responded. Top reasons for MT referral were psychosocial support, pain and symptom management, and coping. The most common symptom-focused indications were anxiety, mood, and existential distress. A variety of factors influenced decisions to refer for MT. Most felt that at least half of their patients could benefit from MT, and nearly all rated MT as “extremely” or “very” effective for improving patients’ quality of life. Suggestions for potential growth for MT in palliative care in the future centered on themes of greater availability, increased variety and collaboration, research opportunities, and staff members’ desire to receive more exposure to MT. Conclusions In this single-institution performance improvement project, staff attitudes were highly favorable toward MT for palliative care patients. MT is utilized for a variety of reasons, can be highly effective for improving patients’ quality of life, and may also be of direct benefit to staff.
NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025
Mehren, Margaret von, Kane, John M., Armstrong, Samantha A., Balach, Tessa, Bishop, Andrew J., Buehler, Darya, Carr-Ascher, Janai, Choy, Edwin, Cipriano, Cara, Connolly, Mary, Dann, Amanda, Davis, Elizabeth J., Dry, Sarah, Eulo, Vanessa, Ganjoo, Kristen N., Gonzalez, Ricardo J., Viveiros, Pedro A. Hermida De, Hitchcock, Ying J., Kim, Edward, Lefler, Daniel, Liebner, David, McCarter, Martin, McGarry, Sean V., Mesko, Nathan W., Meyer, Christian, Motamedi, Kambiz, Movva, Sujana, Pappo, Alberto S., Pollack, Seth M., Poppe, Matthew, Riedel, Richard F., Robinson, Steven, Schuetze, Scott M., Sicklick, Jason K., Tseng, William W., Weiss, Mia C., Zimel, Melissa, Hang, Lisa E., Bergman, Mary Anne, Diwan, Zeenat, Pappo, Alberto S. , Riedel, Richard F. , Riedel, Richard F , Mehren, Margaret von, Kane, John M., Armstrong, Samantha A., Balach, Tessa, Bishop, Andrew J., Buehler, Darya, Carr-Ascher, Janai, Choy, Edwin, Cipriano, Cara, Connolly, Mary, Dann, Amanda, Davis, Elizabeth J., Dry, Sarah, Eulo, Vanessa Anne , Ganjoo, Kristen N., Gonzalez, Ricardo J., Viveiros, Pedro A. Hermida De, Hitchcock, Ying J., Kim, Edward, Lefler, Daniel, Liebner, David, McCarter, Martin, McGarry, Sean V., Mesko, Nathan W., Meyer, Christian, Motamedi, Kambiz, Movva, Sujana, Pollack, Seth M., Poppe, Matthew, Robinson, Steven, Schuetze, Scott M., Sicklick, Jason K., Tseng, William W., Weiss, Mia C., Zimel, Melissa, Hang, Lisa E., Bergman, Mary Anne, Diwan, Zeenat

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 17, 2025 | Volume: 23 | Issue: 12 | Pages: 498-506

10.6004/jnccn.2025.0058 | PMID 41671462 Get It

The treatment landscape for soft tissue sarcomas (STS) is evolving constantly. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for STS specific to surgical management and systemic therapy recommendations for various subtypes.
Prospective, randomized dose-escalation trial with proton-based radiation for skull base and cervical spine chondrosarcomas: 30-year outcomes from PROG 85-26
Ioakeim‐Ioannidou, Myrsini, Yeap, Beow Y., Soetan, Z. , Hegazy, Rana , Todary, Engy S. , Tejada, Athena, Adams, Judith E., Kooy, Hanne M., Zieminski, Stephen, Nielsen, G. Petur, Hung, Yin P. , Rosenberg, Andrew , Shankar, Ganesh M. , Cunnane, Mary E. , Chang, Yuh-Shin , Gardner, Paul A. , Giap, Fantine , DeLaney, Thomas F. , Hug, Eugen B., MacDonald, Shannon M. , Packard, Daniel, Hung, Yin P , Kim, Daniel W. , Packard, Daniel George , Hegazy, Rana, Adams, Judith, Depauw, Nicolas , Rosenberg, Andrew, Tobert, Daniel G , Curry, William T. , Coté, Gregory M. , Kelly, Hillary R. , Chen, Yen‐Lin , Liu, Kevin X , Shih, Helen A.

Mayo Clinic

Neuro-Oncology | December 17, 2025 | Volume: 28 | Issue: 4 | Pages: 968-977

10.1093/neuonc/noaf289 | PMID 41414803 Get It

Abstract Background To determine if dose escalation improves outcomes for chondrosarcomas (CHS) of the base of the skull (BOS) and the cervical spine (CS). Methods A prospective, randomized, dose-escalation trial was designed for patients with CHS of the BOS and CS. Patients were randomly assigned to 70 Gy (RBE) or 76 Gy (RBE). The primary endpoint was local failure (LF). Secondary endpoints included overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), and treatment-related toxicities. Results Between 1987 and 2007, 105 patients were randomized, median follow-up was 29.2 years (IQR, 26.7-32.4). Forty-six patients were assigned to 70 Gy (RBE) and 59 were assigned to 76 Gy (RBE). LF at 5-, 10-, and 20 years were 7%, 9%, and 11% for 70 Gy (RBE), and 10%, 15%, and 19% for 76 Gy (RBE) (P = .16). Like LF rates, there was no benefit in dose escalation for OS (P = .28) and CSS (P = .22). Progression-free survival at 5-, 10-, and 20 years was 93%, 89%, and 77% for the low-dose group and 83%, 71%, and 59% for the high-dose group (P = .069). Late RT injury ≥ grade 3 was reported in a total of 19 (18%) patients across both dose levels, with 11% in the low-dose group and 24% in the high-dose group (P = .13). Conclusions This is the first and largest trial of patients with grade I/II BOS and CS CHS evaluating dose escalation for tumor control. Proton-based RT is effective and safe for these tumors, but there is no apparent benefit in dose escalation. Clinical Trial Information NCT00592748.
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancer
Gore, John L. , Wolff, Erika M. , Nash, Michael G. , Comstock, Bryan A. , Gilbert, Scott M. , Chang, Sam S., Chisolm, Stephanie , MacLean, Douglas B., Wright, Jonathan L. , Kates, Max , Pohar, Kamal S. , Guzzo, Thomas J., Bivalacqua, Trinity J, Nepple, Kenneth G. , Montgomery, Jeffrey S., Scarpato, Kristen R., Master, Viraj A. , Chen, David YT , Mossanen, Matthew , O’Neil, Brock , Tyson, Mark D. , Mansour, Ahmed M. , Chamie, Karim, Riggs, Stephen B. , Kukreja, Janet Baack , Peyton, Cheri L. , Nix, Jeffrey W. , Dickstein, Rian, Sankin, Alex , Lane, Brian R. , Bassett, Jeffrey C. , Patel, Sanjay , Lee, Eugene K. , Ritch, Chad R. , Follmer, Kristin , Kim, Sung Min , Kessler, Larry G. , group, on behalf of the CISTO Collaborative, Gore, John L., Smith, Angela B., Wolff, Erika M., Comstock, Bryan A., Nash, Michael G., Follmer, Kristin M., Lee, Jenney R., Kim, Sung Min, Kessler, Larry G., Gilbert, Scott M., Chang, Sam S., Wright, Jonathan L., Kates, Max R., Pohar, Kamal S., Guzzo, Thomas J., Bivalacqua, Trinity J., Nepple, Kenneth G., Montgomery, Jeffrey S., Scarpato, Kristen R., Woldu, Solomon L., Master, Viraj A., Chen, David Y.T., Mossanen, Matthew, Daneshmand, Siamak, O'Neil, Brock B., Tyson, Mark D., Westerman, Mary E., Kamat, Ashish M., Mansour, Ahmed M., Chamie, Karim, Riggs, Stephen B., Kukreja, Janet B., Modi, Parth K., Garg, Tullika, Peyton, Charles C., Nix, Jeffrey W., Dickstein, Rian, Gadzinski, Adam J., Sankin, Alex, Shore, Neal D., Lane, Brian R., Bassett, Jeffrey C., Patel, Sanjay, Morris, David S., Macleod, Liam C., Lee, Eugene K., Ritch, Chad R., Chisolm, Stephanie, MacLean, Douglas B., Almeida, Fred, Murray, Mary Beth Ballard, Lindsey, Nancy, Lipman, Robert, Oliver, Richard M., Roscoe, Lori A., Sachse, Karen, Lotan, Yair, Porten, Sima P., Taylor, Jennifer M., Steinberg, Gary D., Catto, James W.F., Downs, Tracy M., Malin, Jennifer L., Davicioni, Elai, Rios, Patricia, Yano, Marielle, Jun, Grace, Li, Casey, Nefcy, Christopher, Basu, Anirban, Heagerty, Patrick J., Catto, James W.F. , Sankin, Alexander , Woldu, Solomon L , Master, Viraj A , Chen, David Y T , Daneshmand, Siamak , O'Neil, Brock B , Westerman, Mary E , Kamat, Ashish M. , Modi, Parth K , Peyton, Charles C , Gadzinski, Adam J , Shore, Neal , Patel, Sanjay , Ritch, Chad R , Follmer, Kristin M , Kim, Sung Min , Kessler, Larry G , Bivalacqua, Trinity J. , Daneshmand, Siamak , Westerman, Mary E. , Garg, Tullika K. , Shore, Neal D. , Morris, David S. , Macleod, Liam Connor , Lee, Jenney R. , Smith, Angela B. , group, on behalf of the CISTO Collaborative, Gore, John L., Smith, Angela B., Wolff, Erika M., Comstock, Bryan A., Nash, Michael G., Follmer, Kristin M., Lee, Jenney R., Kim, Sung Min, Kessler, Larry G., Gilbert, Scott M., Chang, Sam S., Wright, Jonathan L., Kates, Max R., Pohar, Kamal S., Guzzo, Thomas J., Bivalacqua, Trinity J., Nepple, Kenneth G., Montgomery, Jeffrey S., Scarpato, Kristen R., Woldu, Solomon L., Master, Viraj A., Chen, David Y.T., Mossanen, Matthew, Daneshmand, Siamak, O'Neil, Brock B., Tyson, Mark D., Westerman, Mary E., Kamat, Ashish M., Mansour, Ahmed M., Chamie, Karim, Riggs, Stephen B., Kukreja, Janet B., Modi, Parth K., Garg, Tullika, Peyton, Charles C., Nix, Jeffrey W., Dickstein, Rian, Gadzinski, Adam J., Sankin, Alex, Shore, Neal D., Lane, Brian R., Bassett, Jeffrey C., Patel, Sanjay, Morris, David S., Macleod, Liam C., Lee, Eugene K., Ritch, Chad R., Chisolm, Stephanie, MacLean, Douglas B., Almeida, Fred, Murray, Mary Beth Ballard, Lindsey, Nancy, Lipman, Robert, Oliver, Richard M., Roscoe, Lori A., Sachse, Karen, Lotan, Yair, Porten, Sima P., Taylor, Jennifer M., Steinberg, Gary D., Catto, James W.F., Downs, Tracy M., Malin, Jennifer L., Davicioni, Elai, Rios, Patricia, Yano, Marielle, Jun, Grace, Li, Casey, Nefcy, Christopher, Basu, Anirban, Heagerty, Patrick J.

Mayo Clinic

Journal of Clinical Oncology | December 15, 2025 | Volume: 44 | Issue: 4 | Pages: 274-285

10.1200/jco-25-01324 | PMID 41397208 Get It

PURPOSE To compare patient-reported and clinical outcomes between radical cystectomy (RC) and bladder-sparing therapy (BST) in patients with recurrent high-grade non–muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS This pragmatic, prospective observational cohort study was designed with patients, who selected and prioritized outcomes. Eligible adults were candidates for both RC or BST, had previous induction Bacillus Calmette-Guérin (BCG), and received their last treatment within 12 months. The primary outcome was the EORTC-QLQ-C30 physical function scale at 12 months. Secondary outcomes included other EORTC-QLQ-C30 scales, depression, anxiety, bladder cancer–specific quality of life (QOL), financial burden, and cancer-specific outcomes. Targeted maximum likelihood estimation (TMLE) was used to calculate average treatment effect (ATE) estimates between arms. Inverse probability weighted risk ratios (wRR) were calculated using quasi-Poisson regression. RESULTS Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC. Physical function was significantly worse in the RC arm at 3 months; by 9 months, there was no difference between arms, and at 12 months, physical function did not differ (ATE, 0.9; 95% CI, –0.6 to 2.4; P = .22). RC was associated with better emotional function, generic health-related QOL, and financial burden, and lower depression and anxiety, while BST was associated with better bowel and sexual health. Cancer-specific survival was 99% for BST versus 96% for RC (wRR, 0.99; 95% CI, 0.97 to 1.01). RC was associated with a higher risk of adverse events and serious adverse events, including a 90-day mortality rate of 2.5%. CONCLUSION Most patient-prioritized outcomes were similar or better among participants who chose RC compared with BST. These findings support the continued role of RC in managing recurrent high-grade NMIBC.
The Risk of Breast Cancer According to Mutation Type and Position in Carriers of a Pathogenic Variant in BRCA1
Apostol, Adriana Ionelia , Metcalfe, Kelly , Jorgji, Dimitri , Cybulski, Cezary , Gronwald, Jacek , Lubiński, Jan , Møller, Pål , Kim, Raymond H. , Aeilts, Amber M. , Cajal, Teresa Ramón y , Pal, Tuya , Bordeleau, Louise , Karlan, Beth Y. , Couch, Fergus J., Zakalik, Dana , Fruscio, Robert , Tung, Nadine, Sun, Ping, Monteiro, Álvaro N.A. , Narod, Steven A. , Akbari, Mohammad R. , Apostol, Adriana I , Jorgji, Dimitri , Cybulski, Cezary , Gronwald, Jacek , Lubinski, Jan , Kim, Raymond H , Aeilts, Amber M , Ramón Y Cajal, Teresa , Pal, Tuya , Karlan, Beth Y , Fruscio, Robert , Monteiro, Alvaro N , Narod, Steven A , Metcalfe, Kelly A , Bordeleau, Louise , Kotsopoulos, Joanne , Singer, Christian F. , Foulkes, William D. , Sun, Ping

Mayo Clinic

Current Oncology | December 15, 2025 | Volume: 32 | Issue: 12 | Pages: 705

10.3390/curroncol32120705 | PMID 41440233 Get It

Background: Carriers of a pathogenic variant (PV) in BRCA1 face a high risk of breast cancer. This study estimated the risk of developing breast cancer according to mutation type and location. Methods: BRCA1 carriers with no personal history of breast cancer or bilateral mastectomy were included. Detailed information on clinical and family history was collected by questionnaire. Survival analysis was used to estimate 15-year cumulative risk according to PV type and location. Results: A total of 3677 BRCA1 carriers were followed for a mean of 7.2 years (range 0.1–15.0 years); 481 incident breast cancers were documented. Overall, the 15-year cumulative incidence was 25%. Risk estimates varied by exon, ranging from 9% (exon 21) to 19% (exon 12) to 36% (exon 15); however, strata were small. Carriers of four founder mutations common in Eastern Europe (c.5263_5264insC, c.181T > G, c.66_67delAG and c.4034delA) experienced a lower-than-expected cancer risk (15.9–24.4%) compared to other PVs (28.8%) (p = 0.02). Conclusions: Although our data suggests some variability in penetrance based on specific BRCA1 PV, this was based on a large number of founder mutations. Breast cancer management strategies should continue to be based on comprehensive risk assessment.
Calibration of Flow Cytometers Enables Reproducible Measurements of Extracellular Vesicle Concentrations and Reference Range Establishment
Bettin, Britta , Li, Bo , Falkena, Kim, Leeuwen, Ton G. van , Gollwitzer, Christian , Varga, Zoltán , Antović, Jovan P. , Berckmans, Pascale , Buzás, Edit I. , Cook, Sean, Dignat‐George, Françoise , Lacroix, Romaric , Maaninka, Katariina , Menezes, Erika G. Marques de , Meyer, Annette, Mizenko, Rachel R. , Nelissen, Inge , Norris, Philip J. , Pink, Desmond , Poudel, Sumeet , Robert, Stéphane, Siljander, Pia , Tang, Vera A. , Broeck, Tina Van Den, Bettin, Britta A , van Leeuwen, Ton G , Ajzenberg, Nadine , Berckmans, Pascale , Buzas, Edit I , Carney, Randy P , Dignat-George, Françoise , Faille, Dorothee , Giebel, Bernd , Jones, Jennifer C , Lacroix, Romaric , Lannigan, Joanne , Lucien, Fabrice , Maaninka, Katariina , de Menezes, Erika G Marques , Mizenko, Rachel R , Nelissen, Inge , Pink, Desmond , Poudel, Sumeet , Siljander, Pia R-M , Tang, Vera A , Tertel, Tobias , Wang, Lili , Welsh, Joshua A , Nieuwland, Rienk , van der Pol, Edwin , Cook, Sean M, Giebel, Bernd , Jones, Jennifer , Kim, Yohan , Lucien, Fabrice , Meyer, Annette, Nolan, John, Welsh, Joshua A , Nieuwland, Rienk

Mayo Clinic

Journal of Extracellular Vesicles | December 15, 2025 | Volume: 14 | Issue: 12 | Pages: No page available

10.1002/jev2.70189 | PMID 41392534 Get It

ABSTRACT The concentration of cells is a key component of modern blood tests. Given the biomarker potential of extracellular vesicles (EVs) in blood, we aimed to establish reference ranges for blood cell‐derived EVs using flow cytometry. To address the orders‐of‐magnitude variability in reported EV concentrations between different flow cytometers (FCMs), we first validated a calibration methodology to enable reproducible EV concentration measurements. The methodology was evaluated in an interlaboratory comparison study and shows that calibration reduces the median absolute deviation of EV concentrations measured on 25 different FCMs from 67 % to 25 %–31 %. The calibration methodology was then used to determine reference ranges of erythrocyte‐, leukocyte‐, and platelet‐derived EVs in human blood plasma in a cohort of healthy individuals ( n = 224). This study demonstrates that calibration enables comparable concentration measurements of blood cell‐derived EVs, thereby bringing EVs one step closer to clinical applications.
Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2
Kotsopoulos, Joanne , Seca, Marta , Gronwald, Jacek, Møller, Pål , Kim, Raymond H. , Singer, Christian F., Karlan, Beth Y. , Aeilts, Amber M. , Cajal, Teresa Ramón y , Eisen, Andrea , Bordeleau, Louise , Tung, Nadine, Neuhausen, Susan L., Zakalik, Dana , Olopade, Olufunmilayo, Metcalfe, Kelly , Sun, Ping, Narod, Steven A., Olopade, Olufunmilayo I. , Singer, Christian F. , Huzarski, Tomasz , Kim, Raymond H , Singer, Christian F , Karlan, Beth Y , Aeilts, Amber M , Ramón Y Cajal, Teresa , Eisen, Andrea , Bordeleau, Louise , Foulkes, William D , Tung, Nadine , Couch, Fergus J. , Neuhausen, Susan L. , Cybulski, Cezary , Olopade, Olufunmilayo I , Fruscio, Robert , Lubinski, Jan , Narod, Steven A , Metcalfe, Kelly A , Kotsopoulos, Joanne , Huzarski, Tomasz , Pal, Tuya , Foulkes, William D. , Tung, Nadine , Couch, Fergus J. , Cybulski, Cezary , Fruscio, Robert , Lubiński, Jan , Narod, Steven A.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | December 13, 2025 | Volume: 118 | Issue: 5 | Pages: 856-864

10.1093/jnci/djaf363 | PMID 41403285 Get It

Abstract Background Women with a pathogenic variant in BRCA1 or BRCA2 are at high risk of developing ovarian cancer, and it is often recommended that they undergo bilateral salpingo-oophorectomy at an early age, resulting in surgical menopause. Menopausal hormone replacement therapy (HRT) is an effective way to mitigate the adverse outcomes of early menopause; however, the safety of menopausal HRT on breast cancer risk in this population has not been established. Methods We conducted a prospective matched analysis of HRT use following menopause and breast cancer risk in BRCA carriers. Women who initiated HRT were matched one-to-one with women who had not initiated menopausal HRT by gene, year of birth, and age at menopause, resulting in 676 matched pairs. Menopausal HRT use collected by questionnaire included formulation and mode of administration. Results After a mean of 5.6 years, there were 87 (12.9%) incident breast cancer cases in the 676 exposed women and 128 (18.9%) cases in the 676 unexposed women (P = .002). Compared with unexposed matched control individuals, women who used estrogen alone experienced a statistically significantly decreased risk of breast cancer (hazard ratio = 0.37, 95% CI = 0.24 to 0.57). No protective or adverse effect was associated with the use of estrogen plus progestogen (hazard ratio = 0.94, 95% CI = 0.54 to 1.63). Conclusions Our findings suggest no substantial increase in the risk of breast cancer in BRCA carriers with the use of HRT and that estrogen alone might be protective.